According to Stephen Rosenfeld, a lawyer with the Prescription Access Litigation Project, which has launched a class-action suit against AstraZeneca and Barr Laboratories over Tamoxifen, an anti-cancer drug, delays to generic drugs mean that 42m Americans who lack health insurance pay a high price, and may not get essential medicines at all.

ECONOMIST: Prescription drugs